Jeremy Chadwick - Kymera Therapeutics Chief Officer
| KYMR Stock | USD 47.02 2.04 4.54% |
Executive
Jeremy Chadwick is Chief Officer of Kymera Therapeutics
| Age | 61 |
| Address | 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472 |
| Phone | 857 285 5300 |
| Web | https://www.kymeratx.com |
Kymera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1538) % which means that it has lost $0.1538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.26) %, meaning that it created substantial loss on money invested by shareholders. Kymera Therapeutics' management efficiency ratios could be used to measure how well Kymera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.35. At this time, Kymera Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 11/26/2024, Non Current Assets Total is likely to grow to about 179 M, while Other Current Assets are likely to drop slightly above 6.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| George Fromm | Shattuck Labs | N/A | |
| Eric JD | Nurix Therapeutics | 57 | |
| Jolie JD | C4 Therapeutics | 47 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Kelli MS | Shattuck Labs | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Christine JD | Nurix Therapeutics | 59 | |
| Kendra Adams | C4 Therapeutics | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Bryant JD | Prelude Therapeutics | 53 | |
| Pasit Phiasivongsa | Nurix Therapeutics | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Conor CPA | Shattuck Labs | N/A | |
| Lindsey Trickett | Prelude Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.15 |
Kymera Therapeutics Leadership Team
Elected by the shareholders, the Kymera Therapeutics' board of directors comprises two types of representatives: Kymera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kymera. The board's role is to monitor Kymera Therapeutics' management team and ensure that shareholders' interests are well served. Kymera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kymera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jared MD, Chief Officer | ||
| DPhil DPHIL, CoFounder Chairman | ||
| JD Esq, Chief Secretary | ||
| Karen Weisbach, Head Culture | ||
| Juliet BA, Head Research | ||
| Melissa Brody, VP Devel | ||
| Elaine Caughey, Chief Officer | ||
| Bruce CFA, Chief Officer | ||
| Dr DPHIL, CoFounder Chairman | ||
| Kevin Dushney, VP Operations | ||
| Vijay Sabesan, VP Operations | ||
| Michael Todisco, VP Fin | ||
| Nello MD, President, CoFounder | ||
| Jeremy Chadwick, Chief Officer |
Kymera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kymera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.91) % | ||||
| Operating Margin | (19.28) % | ||||
| Current Valuation | 2.45 B | ||||
| Shares Outstanding | 64.77 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 98.73 % | ||||
| Number Of Shares Shorted | 9.16 M | ||||
| Price To Book | 3.26 X |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Kymera Stock
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.